Description

(R)-5,7-Difluorochroman-4-Amine is a chiral, fluorinated chroman derivative of significant interest in advanced pharmaceutical research and development. This compound serves as a critical chiral building block and intermediate for the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily utilized by research institutions and pharmaceutical companies engaged in the development of central nervous system (CNS) agents, anti-inflammatory drugs, and other therapeutic candidates where its specific stereochemistry and fluorine substitution pattern are key to biological activity.

Application

• Pharmaceutical Intermediate: A key chiral synthon for the research and development of novel drug candidates, particularly in CNS and anti-inflammatory therapeutic areas.
• Asymmetric Synthesis Building Block: Utilized in the construction of complex molecules requiring the (R)-configured chroman-4-amine scaffold.
• Medicinal Chemistry Research: Employed in structure-activity relationship (SAR) studies to explore the impact of fluorination on potency, metabolic stability, and bioavailability.
• Process Chemistry Development: Serves as a starting material or intermediate in the scale-up and optimization of synthetic routes for target molecules.
• Reference Standard: Used as an analytical standard for quality control and method development in pharmaceutical analysis.

Basic Information

Product Name	(R)-5,7-Difluorochroman-4-Amine
CAS No.	1213103-28-6
Molecular Formula	C9H9F2NO
Molecular Weight	185.17 g/mol
Synonyms	(4R)-5,7-Difluoro-3,4-dihydro-2H-1-benzopyran-4-amine; (R)-5,7-Difluoro-3,4-dihydro-2H-chromen-4-amine; 4-Amino-5,7-difluorochroman, (R)-; 5,7-Difluorochroman-4-amine, (R)-; (R)-4-Amino-5,7-difluorochroman
EINECS	Contact for details

Quality Control

Our (R)-5,7-Difluorochroman-4-Amine is produced under strict quality management systems to ensure high purity and batch-to-batch consistency, suitable for demanding research and development applications. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, enantiomeric excess, and impurity profiles. We adhere to cGMP guidelines for the manufacture of pharmaceutical intermediates, ensuring traceability and documentation for regulatory support.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, well-ventilated area at controlled room temperature (15-25°C). The compound may be hygroscopic; keep the container tightly sealed in a dry environment.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Enantiomeric Excess (Chiral HPLC)	≥ 99.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.